Want to see BCYC full AI Analyst Report?
BCYC Stock Chart & Stats
$5.33
-$0.24(-1.59%)
At close: 4:00 PM EST
$5.33
-$0.24(-1.59%)
Day’s Range― - ―
52-Week Range$3.92 - $9.18
Previous CloseN/A
Volume92.63K
Average Volume (3M)555.85K
Market Cap
$293.47M
Enterprise Value-$220.75
Total Cash (Recent Filing)$559.47M
Total Debt (Recent Filing)$15.34M
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Aug 06, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.15
Shares Outstanding50,373,280
10 Day Avg. Volume374,380
30 Day Avg. Volume555,852
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)0.80
Price to Sales (P/S)6.76
P/FCF Ratio-1.94
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$10.20Price Target Upside91.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.26
Revenue Forecast (FY)$23.14M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and modest absolute debt give Bicycle material financial flexibility to fund clinical programs and absorb near-term setbacks without immediate refinancing. This structural balance sheet strength reduces insolvency risk and preserves optionality for partnerships or targeted funding over months.
Duravelo-2 Clinical ValidationPositive randomized Phase 2 signals (high ORR and manageable safety) materially de-risk the lead program and validate Bicycle’s modality. Durable clinical activity and better tolerability can support strategic partnerships, enrollment acceleration, and progression toward later-stage trials over the medium term.
Pipeline Diversification (EphA2)Advancement of the EphA2 program with confirmatory responses, dose selection, and new Phase 2 starts diversifies the clinical portfolio beyond a single asset. This reduces single-program concentration risk and expands addressable markets in difficult-to-treat tumors over a multi-month horizon.
Bears Say
High Cash BurnSustained ~-$229M annual cash burn is a persistent structural constraint that shortens runway and forces reliance on external financing, partnerships, or milestone receipts. Over 2-6 months this pressure limits the company’s ability to expand trials or scale operations without dilutive or conditional funding.
Entrenched UnprofitabilityVery large operating losses and profoundly negative margins indicate the cost base far exceeds current revenues. This entrenched unprofitability implies a multi-period path to breakeven, making sustained execution and future financing more challenging absent clear clinical/commercial inflection points.
Revenue Volatility And Partner RelianceHistorical revenue growth has been uneven and driven by collaborations and milestone payments rather than product sales. The TTM revenue decline (-12.5%) and partner-dependent cash inflows create lumpy, timing-sensitive funding that complicates budgeting and increases execution risk over the medium term.
Bicycle Therapeutics News
BCYC FAQ
What was Bicycle Therapeutics’s price range in the past 12 months?
Bicycle Therapeutics lowest stock price was $3.92 and its highest was $9.18 in the past 12 months.
What is Bicycle Therapeutics’s market cap?
Bicycle Therapeutics’s market cap is $293.47M.
When is Bicycle Therapeutics’s upcoming earnings report date?
Bicycle Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 16 days.
How were Bicycle Therapeutics’s earnings last quarter?
Bicycle Therapeutics released its earnings results on Apr 30, 2026. The company reported -$0.87 earnings per share for the quarter, missing the consensus estimate of -$0.621 by -$0.249.
Is Bicycle Therapeutics overvalued?
According to Wall Street analysts Bicycle Therapeutics’s price is currently Undervalued.
Does Bicycle Therapeutics pay dividends?
Bicycle Therapeutics does not currently pay dividends.
What is Bicycle Therapeutics’s EPS estimate?
Bicycle Therapeutics’s EPS estimate is -0.56.
How many shares outstanding does Bicycle Therapeutics have?
Bicycle Therapeutics has 50,373,280 shares outstanding.
What happened to Bicycle Therapeutics’s price movement after its last earnings report?
Bicycle Therapeutics reported an EPS of -$0.87 in its last earnings report, missing expectations of -$0.621. Following the earnings report the stock price went down -0.211%.
Which hedge fund is a major shareholder of Bicycle Therapeutics?
Currently, no hedge funds are holding shares in BCYC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bicycle Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.20 (91.37% Upside)
$10.20 (91.37% Upside)
Hedge Fund Trend
Increased
By 63.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $59.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 5.1%
Last 30 Days ▲ 5.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-26.19%
Trailing 12-Months
Company Description
Bicycle Therapeutics
Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's leading investigational product, BT1718, is a Bicycle Toxin Conjugate (BTC) that is undergoing Phase I/IIa clinical trials. This candidate is engineered to target tumors specifically expressing Membrane Type 1 matrix metalloprotease. Other oncology assets in their pipeline include BT5528, also a BTC in Phase I/II studies, which targets EphA2, and BT8009, currently in Phase I/II clinical development, designed to target Nectin-4. Beyond cancer, Bicycle Therapeutics is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase II clinical trials for the treatment of diabetic macular edema. Their portfolio also includes Bicycle tumor-targeted immune cell agonists (TICAs) such as BT7480, which targets Nectin-4, and BT7455, an EphA2/CD137 TICA presently in preclinical development. The company actively fosters collaborations with various biopharmaceutical entities and organizations, broadening its development efforts into therapeutic areas like anti-infectives, cardiovascular conditions, ophthalmology, and respiratory illnesses. Notable partnerships include a clinical trial and license agreement with Cancer Research Technology Limited and Cancer Research UK. They also maintain research collaborations with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund. Furthermore, a significant discovery collaboration and license agreement with Genentech is in place for the identification and development of Bicycle peptides for multiple immuno-oncology targets.
BCYC Stock 12 Month Forecast
Average Price Target
$10.20
▲(91.37% Upside)
Technical Analysis
Ownership Overview
23.05% Insiders
3.43% Mutual Funds
0.22% Other Institutional Investors
72.24% Public Companies and
Individual Investors